Literature DB >> 9104608

Characteristics of injectable contraceptive users in a low-income population in Texas.

H Sangi-Haghpeykar1, A N Poindexter, D C Moseley, L Bateman, E D Reid.   

Abstract

Among 600 women at 17 family planning clinics in Texas who expressed interest in using the hormonal injectable depot medroxyprogesterone acetate (DMPA), 536 (89%) actually received the injectable. Thirty percent of the DMPA recipients were younger than 21 and 77% were not married. The average numbers of pregnancies and births were 1.9 and 1.2 per woman; one-third of the women had had at least one abortion. The majority of women receiving DMPA (66%) were using it to space births. Their main sources of information about the method were friends (42%) and health care providers (37%), and the most commonly reported reason for its use was dissatisfaction with previous contraceptive methods.

Entities:  

Keywords:  Acceptor Characteristics; Acceptors; Age Factors; Americas; Communication; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Demographic Factors; Depo-provera; Developed Countries; Economic Factors; Family Planning; Family Planning Programs; Family Planning Surveys; Knowledge Sources; Low Income Population--women; Marital Status; Medroxyprogesterone Acetate; North America; Northern America; Nuptiality; Population; Population Characteristics; Social Class; Socioeconomic Factors; Socioeconomic Status; Texas; United States

Mesh:

Substances:

Year:  1995        PMID: 9104608

Source DB:  PubMed          Journal:  Fam Plann Perspect        ISSN: 0014-7354


  2 in total

Review 1.  Hormonal Contraceptives and Dermatology.

Authors:  Natalie M Williams; Michael Randolph; Ali Rajabi-Estarabadi; Jonette Keri; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

2.  Women's experiences after Planned Parenthood's exclusion from a family planning program in Texas.

Authors:  C Junda Woo; Hasanat Alamgir; Joseph E Potter
Journal:  Contraception       Date:  2015-12-08       Impact factor: 3.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.